Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.
Adendra Therapeutics has raised $53.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Adendra Therapeutics's investors include Apple Tree Partners.
Adendra Therapeutics is headquartered in London, United Kingdom.
Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.
Adendra Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Adendra Therapeutics — Funding & Investors." VCBacked, December 7, 2021, https://www.vcbacked.co/company/adendra-therapeutics. Accessed September 30, 2026.
VCBacked. (2021). Adendra Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/adendra-therapeutics
{{cite web |title=Adendra Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adendra-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated